“masked” polycythemia vera and polycythemia vera “in evolution”
Published 8 years ago • 5.5K plays • Length 13:49Download video MP4
Download video MP3
Similar videos
-
26:50
“masked” polycythemia vera: time to change who diagnostic criteria
-
19:36
evolution of the assessment of clinical benefit in polycythemia vera
-
19:02
prognostication and initiation of therapy in polycythemia vera: do we have it right?
-
17:25
case study: inadequately controlled polycythemia vera (pv)
-
27:23
interactive case: jak inhibitors for the successful management of polycythemia vera
-
22:40
treatment goals in essential thrombocythemia and polycythemia vera
-
23:39
expert perspectives: jak inhibitors for polycythemia vera
-
25:48
the who updated diagnostic criteria for mpn
-
5:26
what does this patient have: et, pv or masked pv?
-
18:36
diagnostic challenges in mpn
-
19:41
recent advances in the diagnosis, prognosis and survival predictions of patients with pv
-
19:03
assessment of novel treatment options for patients with pv
-
17:25
molecular prognostication in essential thrombocythemia and polycythemia vera: does it matter?
-
20:15
hydroxyurea intolerance/resistance in polycythemia vera
-
17:54
current therapy options and clinical outcomes analysis in patients with pv
-
4:59
behind the mystery, polycythemia vera
-
9:43
polycythemia vera: when to move from hydroxyurea to second-line therapy
-
1:11
dr. hoffman on the current treatment paradigm of polycythemia vera
-
20:53
debate: position of jak2 inhibitors as second line therapy in polycythemia vera